Accuracy of Tumour-Associated Circulating Endothelial Cells as a Screening Biomarker for Clinically Significant Prostate Cancer. - PubMed - NCBI

Accuracy of Tumour-Associated Circulating Endothelial Cells as a Screening Biomarker for Clinically Significant Prostate Cancer. - PubMed - NCBI

Cancers (Basel). 2019 Jul 27;11(8). pii: E1064. doi: 10.3390/cancers11081064.

Accuracy of Tumour-Associated Circulating Endothelial Cells as a Screening Biomarker for Clinically Significant Prostate Cancer.

Bhakdi SC1,2, Suriyaphol P3, Thaicharoen P4, Grote STK4, Komoltri C3, Chaiyaprasithi B5, Charnkaew K6.

Author information

1

Department of Pathobiology, Mahidol University, Bangkok 10400, Thailand. sebastianchakrit.pun@mahidol.ac.th.

2

X-ZELL, 133 Cecil Street, #06-02 Keck Seng Tower, Singapore 069535, Singapore. sebastianchakrit.pun@mahidol.ac.th.

3

Department of Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.

4

X-ZELL, 133 Cecil Street, #06-02 Keck Seng Tower, Singapore 069535, Singapore.

5

Division of Urology, Department of Surgery, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.

6

Department of Pathology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.

Abstract

Even though more than 350,000 men die from prostate cancer every year, broad-based screening for the disease remains a controversial topic. Guidelines demand that the only commonly accepted screening tool, prostate-specific antigen (PSA) testing, must be followed by prostate biopsy if results are elevated. Due to the procedure's low positive predictive value (PPV), however, over 80% of biopsies are performed on healthy men or men with clinically insignificant cancer-prompting calls for new ways of vetting equivocal PSA readings prior to the procedure. Responding to the challenge, the present study investigated the diagnostic potential of tumour-associated circulating endothelial cells (tCECs), which have previously been described as a novel, blood-based biomarker for clinically significant cancers. Specifically, the objective was to determine the diagnostic accuracy of a tCEC-based blood test to detect clinically significant prostate cancer (defined as Gleason score ≥ 3 + 4) in high-risk patients. Performed in a blinded, prospective, single-centre set-up, it compared a novel tCEC index test with transrectal ultrasound-guided biopsy biopsy as a reference on a total of 170 patients and found that a tCEC add-on test will almost double the PPV of a standalone PSA test (32% vs. 17%; p = 0.0012), while retaining a negative predictive value above 90%.

KEYWORDS:

PSA; clinically significant prostate cancer; diagnostic accuracy; grey zone; liquid biopsy; prostate cancer screening; tCEC; tumour-associated circulating endothelial cells

PMID:

 

31357651

 

DOI:

 

10.3390/cancers11081064

Free full text